Detalhe da pesquisa
1.
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study.
Eur J Neurol
; 28(4): 1299-1307, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33305459
2.
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
Mult Scler
; 24(6): 813-815, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29359617
3.
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Ann Neurol
; 80(1): 89-100, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27145331
4.
Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial.
Health Expect
; 17(1): 36-48, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22040528
5.
Data of safety in a single-center alemtuzumab treated population.
Data Brief
; 29: 105341, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32181303
6.
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
J Neurol
; 265(12): 2851-2860, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30259178
7.
Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis.
J Neurol
; 251(10): 1208-14, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15503099